{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:37:01Z","timestamp":1784248621304,"version":"3.55.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Livedoid vasculopathy (LV) is a rare, non-inflammatory, intradermal vascular obstructive skin disorder characterized by purpuric papules and plaques with capillary dilation. These lesions typically progress to crusted ulcers and ultimately result in fixed, white, atrophic stellate scars. The condition is marked by painful ulcers that heal slowly and have a tendency to recur.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We report a case of a pediatric patient presenting with recurrent rashes and pain in both lower extremities. Physical examination revealed purpuric plaques with ulceration, scarring, and white atrophic healing features. Histopathological examination demonstrated intradermal thrombosis, vessel wall necrosis, and surrounding inflammatory cell infiltration with erythrocyte extravasation. Periodic acid-Schiff (PAS) staining was positive. The clinical and pathological findings were consistent with a diagnosis of LV. The patient was treated with oral rivaroxaban.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case highlights the critical importance of early recognition and intervention in the management of LV. Clinicians should consider LV in the differential diagnosis when encountering patients with painful purpuric rashes. Improvement in pain following treatment with anticoagulants, such as rivaroxaban, may indirectly support the diagnosis. A skin biopsy is essential for definitive diagnosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1537133","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:38:15Z","timestamp":1747201095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A case report and literature review of livedoid vasculopathy in children"],"prefix":"10.3389","volume":"13","author":[{"given":"Jing","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Junli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ad.2020.10.004","article-title":"Clinical and histopathologic characteristics of the main causes of vascular occusion\u2014part II: coagulation disorders, emboli, and other","volume":"112","author":"Beato Merino","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ijwd.2021.08.013","article-title":"Livedoid vasculopathy: a multidisciplinary clinical approach to diagnosis and management","volume":"7","author":"Bilgic","year":"2021","journal-title":"Int J Womens Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/1358863X221130380","article-title":"Livedoid vasculopathy: a review with focus on terminology and pathogenesis","volume":"27","author":"Eswaran","year":"2022","journal-title":"Vasc Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/iwj.13563","article-title":"Livedoid vasculopathy and its association with genetic variants: a systematic review","volume":"18","author":"Gao","year":"2021","journal-title":"Int Wound J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.4103\/0378-6323.183635","article-title":"Livedoid vasculopathy: a review of pathogenesis and principles of management","volume":"82","author":"Vasudevan","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaad.2013.07.019","article-title":"Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach","volume":"69","author":"Alavi","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e14569","DOI":"10.1111\/dth.14569","article-title":"Livedoid vasculopathy: clinical course and long-term outcome in Asian patients with a review of the literature","volume":"34","author":"Rujitharanawong","year":"2021","journal-title":"Dermatol. Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1111\/jdv.15830","article-title":"Livedoid vasculopathy: how to diagnose and how to treat?","volume":"33","author":"Lipsker","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaad.2014.06.030","article-title":"Quality-of-life impairment in patients with livedoid vasculopathy","volume":"71","author":"Polo Gasc\u00f3n","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1111\/iwj.13480","article-title":"Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy","volume":"17","author":"Gao","year":"2020","journal-title":"Int Wound J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1097\/CM9.0000000000001048","article-title":"Clinical and dermoscopic features of livedoid vasculopathy","volume":"133","author":"Wen","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e28485","DOI":"10.7759\/cureus.28485","article-title":"Comparative efficacy of rivaroxaban and immunoglobulin therapy in the treatment of livedoid vasculopathy: a systematic review","volume":"14","author":"Ramphall","year":"2022","journal-title":"Cureus"},{"key":"B13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/bjd.12100","article-title":"Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy","volume":"168","author":"Kerk","year":"2013","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e15051","DOI":"10.1111\/dth.15051","article-title":"Rivaroxaban for treatment of livedoid vasculopathy: a systematic review","volume":"34","author":"Gao","year":"2021","journal-title":"Dermatol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/ced\/llae023","article-title":"Associations between coagulation factors and livedoid vasculopathy and the efficacy and safety of rivaroxaban in patients with livedoid vasculopathy: a retrospective study","volume":"49","author":"Zhao","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e14470","DOI":"10.1111\/dth.14470","article-title":"Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib","volume":"33","author":"Jia","year":"2020","journal-title":"Dermatol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2147\/CCID.S455903","article-title":"Anti-Interleukin 17A biologic therapy attempts on livedoid vasculopathy: a report of case series","volume":"17","author":"Qi","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1537133\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:38:16Z","timestamp":1747201096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1537133\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":17,"alternative-id":["10.3389\/fped.2025.1537133"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1537133","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"1537133"}}